12 Aug 2013


(“Sareum” or “the Company”)

Pre-Close Trading Statement

Sareum, the specialist cancer drug discovery business, is pleased to provide the following pre-close trading update for the year ending 30 June 2013.

The Company expects that its financial results for the year ended 30 June 2013 will be slightly ahead of market expectations, with the loss for the year after tax anticipated to be approximately £540,000.

The Company expects to report its full year results for the year ended 30 June 2013 in mid-October 2013.

Sareum's CEO, Dr. Tim Mitchell, said:

“This has been another year of good progress for Sareum. We continue to work towards completing commercialisation opportunities for our Chk1 and Aurora+FLT3 programmes that we believe will give the best return to shareholders.  Research on our TYK2 and FASN programmes is progressing well, the former benefiting from the collaboration with SRI International and the latter supported by grant funding from the Biomedical Catalyst.  We look forward to reporting on our progress in greater detail in October.”

For further information:


Sareum Holdings plc


Tim Mitchell

01223 497 700

Sanlam Securities UK Limited (Nomad)

Simon Clements

020 7628 2200

Hybridan LLP (Broker)


Claire Noyce, William Lynne

020 7947 4350 / 020 7947 4361

Media enquiries:


The Communications Portfolio Ltd


Ariane Comstive

020 7536 2028



Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR.  For further information, please visit www.sareum.co.uk